Vedolizumab and etrolizumab for ulcerative colitis: twins or simple cousins?

References

• Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet. 2017;389(10080):1756–1770.
   PubMed Web of Science ®Google Scholar
• Waljee AK, Joyce JC, Wren PA, et al. Patient reported symptoms during an ulcerative colitis flare: a qualitative focus group study. Eur J Gastroenterol Hepatol. 2009;21(5):558–564.
   PubMed Web of Science ®Google Scholar
• Autenrieth DM, Baumgart DC. Toxic megacolon. Inflamm Bowel Dis. 2012;18(3):584–591.
   PubMed Web of Science ®Google Scholar
• Beaugerie L, Itzkowitz SH, Longo DL. Cancers complicating inflammatory bowel disease. N Engl J Med. 2015;372(15):1441–1452.
   PubMed Web of Science ®Google Scholar
• Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491(7422):119–124.
   PubMed Web of Science ®Google Scholar
• Műzes G, Molnár B, Tulassay Z, et al. Changes of the cytokine profile in inflammatory bowel diseases. World J Gastroenterol. 2012;18(41):5848–5861.
   PubMed Web of Science ®Google Scholar
• Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of Ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017;11(7):769–784. .
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–2476.
   PubMed Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60(6):780–787.
   PubMed Web of Science ®Google Scholar
• Roda G, Jharap B, Neeraj N, et al. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016;7:e135.
   PubMed Web of Science ®Google Scholar
• Zundler S, Becker E, Schulze LL, et al. Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances. Gut. 2019;68(9):1688–1700.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2005;353(18):1912–1925.
   PubMed Web of Science ®Google Scholar
• Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE trial. Gastroenterology. 2007;132(5):1672–1683.
   PubMed Web of Science ®Google Scholar
• Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899–910.
   PubMed Web of Science ®Google Scholar
• Schwab N, Schneider-Hohendorf T, Melzer N, et al. Natalizumab-associated PML: challenges with incidence, resulting risk, and risk stratification. Neurology. 2017;88(12):1197–1205.
   PubMed Web of Science ®Google Scholar
• Fedyk ER, Wyant T, Yang -L-L, et al. Exclusive antagonism of the α4 β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates. Inflamm Bowel Dis. 2012;18(11):2107–2119.
   PubMed Web of Science ®Google Scholar
• Rutgeerts PJ, Fedorak RN, Hommes DW, et al. A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis. Gut. 2013;62(8):1122–1130.
   PubMed Web of Science ®Google Scholar
• Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014;14(5):329–342.
   PubMed Web of Science ®Google Scholar
• Lobatón T, Vermeire S, Van Assche G, et al. Review article: anti-adhesion therapies for inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39(6):579–594.
   PubMed Web of Science ®Google Scholar
• Lamb CA, O’Byrne S, Keir ME, et al. Gut-selective integrin-targeted therapies for inflammatory bowel disease. J Crohns Colitis. 2018;12(suppl_2):S653–68.
   PubMedGoogle Scholar
• Wyant T, Fedyk E, Abhyankar B. An overview of the mechanism of action of the monoclonal antibody vedolizumab. J Crohns Colitis. 2016;10(12):1437–1444.
   PubMed Web of Science ®Google Scholar
• Tsuzuki Y, Miura S, Suematsu M, et al. alpha 4 integrin plays a critical role in early stages of T lymphocyte migration in Peyer’s patches of rats. Int Immunol. 1996;8(3):287–295.
   PubMed Web of Science ®Google Scholar
• Salmi M, Alanen K, Grenman S, et al. Immune cell trafficking in uterus and early life is dominated by the mucosal addressin MAdCAM-1 in humans. Gastroenterology. 2001;121(4):853–864.
   PubMed Web of Science ®Google Scholar
• Elewaut D, Van Damme N, De Keyser F, et al. Altered expression of alpha E beta 7 integrin on intra-epithelial and lamina propria lymphocytes in patients with Crohn’s disease. Acta Gastroenterol Belg. 1998;61(3):288–294.
   PubMed Web of Science ®Google Scholar
• Zundler S, Schillinger D, Fischer A, et al. Blockade of αEβ7 integrin suppresses accumulation of CD8+ and Th9 lymphocytes from patients with IBD in the inflamed gut in vivo. Gut. 2017;66(11):1936–1948. .
   PubMed Web of Science ®Google Scholar
• Annacker O, Coombes JL, Malmstrom V, et al. Essential role for CD103 in the T cell-mediated regulation of experimental colitis. J Exp Med. 2005;202(8):1051–1061.
   PubMed Web of Science ®Google Scholar
• Rosario M, Dirks NL, Milch C, et al. A review of the clinical pharmacokinetics, pharmacodynamics, and immunogenicity of vedolizumab. Clin Pharmacokinet. 2017;56(11):1287–1301.
   PubMed Web of Science ®Google Scholar
• Overstreet MG, Gaylo A, Angermann BR, et al. Inflammation-induced interstitial migration of effector CD4+ T cells is dependent on integrin αV. Nat Immunol. 2013;14(9):949–958.
   PubMed Web of Science ®Google Scholar
• Yu Y, Zhu J, Mi L-Z, et al. Structural specializations of α(4)β(7), an integrin that mediates rolling adhesion. J Cell Biol. 2012;196(1):131–146.
   PubMed Web of Science ®Google Scholar
• Soler D, Chapman T, Yang -L-L, et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009;330(3):864–875.
   PubMed Web of Science ®Google Scholar
• Wyant T, Yang L, Fedyk E. In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes. MAbs. 2013;5(6):842–850.
   PubMed Web of Science ®Google Scholar
• Rosario M, Wyant T, Leach T, et al. Vedolizumab pharmacokinetics, pharmacodynamics, safety, and tolerability following administration of a single, ascending, intravenous dose to healthy volunteers. Clin Drug Investig. 2016;36(11):913–923.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699–710.
   PubMed Web of Science ®Google Scholar
• Bian S, Dreesen E, Tang HT, et al. Antibodies toward vedolizumab appear from the first infusion onward and disappear over time. Inflamm Bowel Dis. 2017;23(12):2202–2208.
   PubMed Web of Science ®Google Scholar
• Andrew DP, Berlin C, Honda S, et al. Distinct but overlapping epitopes are involved in alpha 4 beta 7-mediated adhesion to vascular cell adhesion molecule-1, mucosal addressin-1, fibronectin, and lymphocyte aggregation. J Immunol. 1994;153(9):3847–3861.
   PubMed Web of Science ®Google Scholar
• Wu T, Hu Y, Lee Y-T, et al. Lung-resident memory CD8 T cells (TRM) are indispensable for optimal cross-protection against pulmonary virus infection. J Leukoc Biol. 2014;95(2):215–224.
   PubMed Web of Science ®Google Scholar
• Prasad S, Hu S, Sheng WS, et al. Reactive glia promote development of CD103+ CD69+ CD8+ T-cells through programmed cell death-ligand 1 (PD-L1). Immun Inflamm Dis. 2018;6(2):332–344.
   PubMed Web of Science ®Google Scholar
• Cepek KL, Parker CM, Madara JL, et al. Integrin alpha E beta 7 mediates adhesion of T lymphocytes to epithelial cells. J Immunol. 1993;150(8 Pt 1):3459–3470.
   PubMed Web of Science ®Google Scholar
• Lichnog C, Klabunde S, Becker E, et al. Cellular mechanisms of etrolizumab treatment in inflammatory bowel disease. Front Pharmacol. 2019;10:39.
   PubMed Web of Science ®Google Scholar
• Vermeire S, O’Byrne S, Keir M, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet. 2014;384(9940):309–318.
   PubMed Web of Science ®Google Scholar
• Research C for DE and. Drug trials snapshot: Entyvio (vedolizumab) to treat ulcerative colitis. FDA 2019.
   Google Scholar
• Anonymous. Entyvio. European medicines agency. cited 2019 Dec 4. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/entyvio.
   Google Scholar
• Feagan BG, Schreiber S, Wolf DC, et al. Sustained clinical remission with vedolizumab in patients with moderate-to-severe ulcerative colitis. Inflamm Bowel Dis. 2019;25(6):1028–1035.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Colombel J-F, Panaccione R, et al. Deep remission with vedolizumab in patients with moderately to severely active ulcerative colitis: a GEMINI 1 post hoc analysis. J Crohns Colitis. 2019;13(2):172–181.
   PubMed Web of Science ®Google Scholar
• Loftus EV, Colombel J-F, Feagan BG, et al. Long-term efficacy of vedolizumab for ulcerative colitis. J Crohns Colitis. 2017;11(4):400–411.
   PubMed Web of Science ®Google Scholar
• Colombel J-F, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut. 2017;66(5):839–851.
   PubMed Web of Science ®Google Scholar
• Arijs I, De Hertogh G, Lemmens B, et al. Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC. Gut. 2018;67(1):43–52.
   PubMed Web of Science ®Google Scholar
• Engel T, Ungar B, Yung DE, et al. Vedolizumab in IBD-lessons from real-world experience; a systematic review and pooled analysis. J Crohns Colitis. 2018;12(2):245–257.
   PubMed Web of Science ®Google Scholar
• Vande Casteele N, Herfarth H, Katz J, et al. American Gastroenterological Association Institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases. Gastroenterology. 2017;153(3):835–857.e6.
   PubMed Web of Science ®Google Scholar
• Dreesen E, Verstockt B, Bian S, et al. Evidence to support monitoring of vedolizumab trough concentrations in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2018;16(12):1937–1946.e8.
   PubMed Web of Science ®Google Scholar
• Pouillon L, Rousseau H, Busby-Venner H, et al. Vedolizumab trough levels and histological healing during maintenance therapy in ulcerative colitis. J Crohns Colitis. 2019;13(8):970–975.
   PubMed Web of Science ®Google Scholar
• Singh S, Dulai PS, Vande Casteele N, et al. Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases. Aliment Pharmacol Ther. 2019;50(8):848–857.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Chaparro M. Predictors of primary response to biologic treatment (anti-TNF, vedolizumab and ustekinumab) in patients with inflammatory bowel disease: from basic science to clinical practice. J Crohns Colitis. 2019. DOI:10.1093/ecco-jcc/jjz195
   Google Scholar
• Amiot A, Grimaud J-C, Peyrin-Biroulet L, et al. Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2016;14(11):1593–1601.e2.
   PubMed Web of Science ®Google Scholar
• Shmidt E, Kochhar G, Hartke J, et al. Predictors and management of loss of response to vedolizumab in inflammatory bowel disease. Inflamm Bowel Dis. 2018;24(11):2461–2467.
   PubMed Web of Science ®Google Scholar
• Document. cited 2019 Dec 4. Available from: https://www.ueg.eu/education/document/etrolizumab-induction-therapy-improved-endoscopic-score-patient-reported-outcomes-and-inflammatory-biomarkers-in-patients-with-moderate-to-severe-uc-who-had-failed-tnf-antagonist-therapy-results-from-the-hickory-open-label-induction-oli-trial/151598/.
   Google Scholar
• Tew GW, Hackney JA, Gibbons D, et al. Association between response to etrolizumab and expression of integrin αe and granzyme a in colon biopsies of patients with ulcerative colitis. Gastroenterology. 2016;150(2):477–487.e9. .
   PubMed Web of Science ®Google Scholar
• Binder M-T, Becker E, Wiendl M, et al. Similar inhibition of dynamic adhesion of lymphocytes from IBD patients to MAdCAM-1 by vedolizumab and etrolizumab-s. Inflamm Bowel Dis. 2018;24(6):1237–1250.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, Colombel J-F, et al. Incidence of arthritis/arthralgia in inflammatory bowel disease with long-term vedolizumab treatment: post hoc analyses of the gemini trials. J Crohns Colitis. 2019;13(1):50–57.
   PubMed Web of Science ®Google Scholar
• Tadbiri S, Peyrin-Biroulet L, Serrero M, et al. Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort. Aliment Pharmacol Ther. 2018;47(4):485–493.
   PubMed Web of Science ®Google Scholar
• Dubash S, Marianayagam T, Tinazzi I, et al. Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease. Rheumatology (Oxford). 2019;58(6):963–968.
   PubMed Web of Science ®Google Scholar
• Singh S, Fumery M, Sandborn WJ, et al. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis. Aliment Pharmacol Ther. 2018;47(2):162–175.
   PubMed Web of Science ®Google Scholar
• Sands BE, Peyrin-Biroulet L, Loftus EV, et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med. 2019;381(13):1215–1226. .
   PubMed Web of Science ®Google Scholar
• Zundler S, Becker E, Spocinska M, et al. Hobit- and Blimp-1-driven CD4+ tissue-resident memory T cells control chronic intestinal inflammation. Nat Immunol. 2019;20(3):288–300.
   PubMed Web of Science ®Google Scholar